France· FR:61447763
VOLIBRIS 2,5 mg, comprimés pelliculés
A ambrisentan product containing ambrisentan, registered in France by GLAXOSMITHKLINE TRADING SERVICES (IRLANDE). The same ATC class is registered in 18 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Ambrisentan is registered in 18 of 19 countries.
Countries holding a registration under ATC C02KX02 (ambrisentan), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Ambrisentan · ATC C02KX02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ambrisentan costs, country by country.
Normalised to the WHO defined daily dose (7.5 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ambrisentan · price per daily dose (7.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$54.19
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- AMBRISENTAN
- Manufacturer
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Country
- France (FR)
- ATC code
- C02KX02
- ATC class
- Ambrisentan
- Defined daily dose
- 7.5 mg, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009302408781 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimé(s)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
155 interactions on record for ambrisentan.
Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ambrisentan · interactions on record
155 records
- 5 severe
- 71 moderate
- 12 minor
- 67 info
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- CiclosporinL04AD01severe
- LeflunomideL04AK01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ambrisentan in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumAmbrisentan Accord 2.5 mgAccord Healthcare
- CzechiaVOLIBRISGlaxoSmithKline Trading Services Limited, Dublin
- SpainVOLIBRIS 2,5 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandVolibrisGlaxoSmithKline Trading Services Limited
- IrelandVolibris 2.5 mg film-coated tabletGlaxoSmithKline Trading Services Limited
- IcelandVolibrisGlaxoSmithKline Trading Services Limited
- NetherlandsVolibris 2,5 mg filmomhulde tablettenGlaxoSmithKline Trading Services Limited
- PolandVolibrisGlaxoSmithKline (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 26 EEA countries. Names it is sold under:
- Austria · Ambrisentan Accord, Ambrisentan Aop
- Belgium · Ambrisentan Accord, Ambrisentan Sandoz
- Bulgaria · Aмбрисентан Aкорд, Амбрисентан Зентива
- Cyprus · Ambrisentan Msn, Ambrisentan Sapiens
- Czechia · Ambrisentan Accord, Ambrisentan Sandoz
- Germany · Ambripuren, Ambrisentan
- Denmark · Ambrisentan "sandoz", Ambrisentan Accord
- Estonia · Ambrisentan Inteli, Ambrisentan Norameda
- Spain · Ambrisentan Accord, Ambrisentán Aurovitas
- Finland · Ambrisentan Accord
- United Kingdom (Northern Ireland) · Ambrisentan Accord, Ambrisentan Axunio
- Greece · Ambicipen, Ambrisentan Accord
- Croatia · Ambrisentan Accord
- Hungary · Ambrisentan Azr
- Ireland · Ambrisentan Accord
- Iceland · Ambrisentan Viatris, Volibris
- Italy · Ambrisentan Accord, Ambrisentan Medac
- Liechtenstein · Ambrisentan Viatris, Volibris
- Lithuania · Ambrisentan Aop, Ambrisentan Inteli
- Latvia · Ambrisentan Inteli, Ambrisentan Norameda
- Netherlands · Ambrisentan Accord, Ambrisentan Aop
- Norway · Ambrisentan Accord, Ambrisentan Viatris
- Portugal · Ambrisentano Accord, Ambrisentano Generis
- Sweden · Ambrisentan Accord, Ambrisentan Bluefish
- Slovenia · Ambrisentan Accord
- Slovakia · Ambrisentan Aop
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cf97ffb2-936c-4120-b998-da10d68a9260 GET /v1/drugs/cf97ffb2-936c-4120-b998-da10d68a9260?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "61447763",
"date_amm": "2021-09-22",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/08/451",
"substance": "AMBRISENTAN",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ambrisentan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.